The release also doesn’t mention potential harms of PCI, put the size of the benefit in context, or disclose conflicts of interest.
Compared to many news releases we review that have to do with rodent research, this one was more cautious with its language than most.
The story also makes clear that this finding is not robust enough to change treatment guidelines yet and that other outcomes, such as quality of life improvement are still being analyzed.
NBC News story doesn’t adequately scrutinize the claims being made about a new drug to prevent migraines.
Based on the information in the release, the device appears to be — at this point — little more than a concept.
The release neglects to mention that even after this phase 2 trial has been completed, researchers won’t know if the experimental drug cocktail is better or worse than standard treatments, because it does not include any direct comparison.
This story never cites a specific study, nor does it provide links to several existing studies documenting benefits and harms.
News release recruiting patients for a phase 1 trial skips almost every detail a patient needs to know: what’s different about the device, success rate of similar devices, harms, and more.